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Abstract 
Cardiovascular diseases are a main cause of morbidity and mortality worldwide and its prevention is a 
major concern in current practical guidelines. Reduction of low-density lipoprotein cholesterol (LDL-c) 
plasma levels lower than 70 mg/dL in patients with established cardiovascular disease, sometimes 
cannot be achieved, despite maximum-tolerated statin dose. The proprotein convertase subtilisin/kenin 
9 inhibitors have recently emerged and showed an incremental reduction in LDL-c levels in this patient 
setting and a reduction of major adverse cardiovascular events have been clearly established. Several 
randomized controlled trials regarding the clinical effects of evolocumab, alirocumab and bococizumab 
have been published in the latest years and some of them are described in this article. Physicians might 
be looking towards a very useful lipid-lowering therapy for high cardiovascular risk patients. 
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Resumo  
As doenças cardiovasculares são uma causa importante de morbimortalidade em todo o mundo e a sua 
prevenção constitui um assunto importante nas guidelines práticas atuais. A redução dos níveis 
plasmáticos de lipoproteínas de colesterol de baixa densidade (c-LDL) abaixo de 70 mg/dL em doentes 
com doença cardiovascular estabelecida, por vezes, não consegue ser alcançada, apesar da dose máxima 
tolerada de estatinas. Os inibidores proproteina convertase subtilisina/kenina 9 (PCSK9) emergiram 
recentemente mostrando uma redução adicional nos níveis de c-LDL neste grupo de doentes, assim 
como redução inequívoca nos eventos cardiovasculares major. Vários ensaios clínicos randomizados 
centrados nos efeitos clínicos do evolocumab, alirocumab e bococizumab têm sido publicados nos 
últimos anos e estando alguns deles são descritos neste artigo. A comunidade médica poderá estar a 
olhar em direção a uma terapêutica de redução lipídica muito útil em doentes com elevado risco 
cardiovascular. 
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 Abbreviations Table 
Designation English Portuguese 
3-hidroxi-3-methyl-glutaril-CoA HMG-CoA HMG-CoA 
Absolute risk reduction AAR RRA 
Acute coronary syndrome ACS SCA 
High-sensitivity C reactive protein hs-CRP PCR-as 
Cambridge Neuropsychological Test 
Automated battery 
CANTAB CANTAB 
Cardiovascular diseases CVD DCV 
Confidence interval CI IC 
Coronary heart disease CHD DAC 
Everyday cognition tool ECog ECog 
Hazard ratio HR HR 
LDL-cholesterol LDL-c c-LDL 
LDL receptor LDLR RLDL 
Major adverse limb events MALE EAMM 
Major adverse cardiovascular events MACE EACM 
Myocardial infarction MI EAM 
Number needed to treat NNT NNT 
Number n n 
Percent atheroma volume PAV VAP 
Peripheral artery disease PAD DAP 
Proprotein convertase subtilisin/kenin 9 PCSK9 PCSK9 
Total atheroma volume TAV VAT 
 
 
 
 
 
 
 
 
 
Introduction 
Cardiovascular diseases (CVD) remain a leading cause of morbidity and mortality worldwide (1). 
Secondary CVD prevention is crucial in our society since more patients survive their first episode of 
cardiovascular event and are at higher risk of recurrence (2, 3).  
In this review, among the treatment targets and goals for CVD prevention, the author will focus only in 
hypercholesteremia. LDL-cholesterol (LDL-c) is a well-established and modifiable risk factor for CVD. 
Currently, an LDL-c goal of less than 70 mg/dl is recommended in very high-risk patients. To achieve 
these plasma levels, not only a lifestyle modification but also medical treatment is required (2).  
Statins remain the first-line drug for lipid management in patients with atherosclerotic CVD by 
inhibiting 3-hidroxi-3-methyl-glutaril-CoA (HMG-CoA) reductase (4). Although these drugs are safe, 
some patients experience adverse events or are intolerant to them, or do not achieve LDL-c goals despite 
maximum tolerated statin-dose (5). In either case, the second line therapy available is ezetimibe, a 
cholesterol absorption inhibitor, which not only provides an additional reduction in LDL-c levels when 
associated to a statin, but also significantly reduces major adverse cardiovascular events (MACE) (6). 
Even with an optimized regimen, some patients still do not reach their LDL-c goals. To accomplish that, 
a novel class of drugs, the proprotein convertase subtilisin/kenin 9 (PCSK9) inhibitors, had recently 
emerged (7). Evolocumab, alirocumab and bococizumab, are the three most studied PCSK9 inhibitors (8).  
PCSK9 is produced mostly in the liver and binds to LDL receptors (LDLR) on hepatic cell surface. It 
targets the LDLR for degradation inside hepatic cell endosome. Consequently, the LDLR is not recycled 
to the hepatic cell surface resulting in fewer LDLR available to capture LDL-c on plasma. Ultimately, 
a rise in LDL-c levels on plasma occurs (9). Thus, when using a PCSK9 inhibitor, the LDLR is not 
degraded and is able to return to the cell surface. This results in a decrease in LDL-c plasma levels 
(figure 1). Recently, Toth PP et al. showed that PCSK9 inhibitors were associated with a significant 
reduction in LDL-c plasma levels compared to either placebo and ezetimibe (10). 
It is important to establish if incremental reduction in LDL-c plasma levels prevents cardiovascular 
events and overall mortality (11). 
The main goal of this narrative review is to provide a summarized description of the major randomized 
controlled trials regarding the efficacy and clinical effects of evolocumab, alirocumab and bococizumab 
on CVD. 
The current report was not funded by any interested party, either governmental or industry, and the 
decision to carry out this review was taken exclusively by the author. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Methods 
Search Strategy 
This study started with a research on two data bases, Pubmed and ISI Web of Knowledge, using the 
queries ‘’ (evolocumab OR alirocumab OR bococizumab) AND Randomized Controlled Trial [Filter]’’, 
‘’evolocumab’’ AND ‘’clinical trial’’, ‘’alirocumab’’ AND ‘’clinical trial’’, ‘’bococizumab’’ AND 
‘’clinical trial’’. The search took place in November 2018 and no articles were excluded based on 
publication date. The aim of this search was to identify randomized controlled trials regarding 
evolocumab, alirocumab and bococizumab. The queries resulted in 463 articles. A flowchart showing 
the literature search method, as well as the resulting number of articles selected, is displayed in Figure 
2. 
 
Inclusion criteria  
Randomized controlled trials whose primary end-point is a clinical outcome were included.  
Published ad-hoc exploratory analysis of the selected trials, if considered relevant by the author, may 
also have been included in the report. 
Exclusion criteria 
Studies other than randomized controlled trials whose primary end-point is a clinical outcome were 
excluded. Case reports, retrospective studies, observational studies other than randomized controlled 
trials and systematic reviews were therefore excluded. Randomized controlled trials whose primary end-
point was change in LDL-c level from baseline overtime alone, although relevant, were considered 
outside the scope of this review.  
 
 
 
Major Randomized Controlled Trials  
Studies involving Evolocumab 
OSLER (2015)  
Sabatine et al. enrolled patients that had completed a parent phase 2 or phase 3 trial of evolocumab (12-
21), respectively, into one of two longer-term extension trials, designated Open-Label Study of Long-
Term Evaluation against LDL Cholesterol 1 and 2 (OSLER-1 and -2) (22). 
 Patients were eligible if they did not have an adverse event that led to the discontinuation of a study 
drug during the parent trial, did not have an unstable medical condition, and were not expected to need 
unblinded lipid measurement or adjustment of background lipid-regulating therapy during the first 12 
weeks of participation in the OSLER trials. 
A total of 4465 patients were enrolled in the OSLER program (1342 patients in OSLER-1 and 3141 
patients in OSLER-2) 
Eligible patients were randomly assigned to receive either evolocumab plus standard therapy (n=2976) 
or standard therapy alone (n=1489), regardless of their study-group in the parent study. Evolocumab 
was administered monthly, subcutaneously, at a dose of 420mg in OSLER-1 and 140mg twice a week 
or 420mg monthly in OSLER-2.  
The median duration of follow-up was 11.1 months. 
The primary end-point was the incidence of adverse events. It occurred in 2060 patients (69.2%) in the 
evolocumab group and in 965 patients (64.8%) in the standard therapy group. Serious adverse events 
occurred in 222 patients (7.5%) in the evolocumab group and in 111 patients (7.5%) in the standard-
therapy group. 
The secondary end-point was the percent change in the LDL cholesterol level, which was reduced by 
61% (95% CI, 59 to 63; P<0.001) in the evolocumab group compared to standard-therapy group at 12 
week and was maintained over time. 
An exploratory analysis showed an all cardiovascular events reduction in evolocumab group compared 
to standard-therapy group (Kaplan-Meier estimates at 1 year, 0.95% and 2.18%, respectively; HR=0.47; 
95% CI, 0.28 to 0.78; P=0.003).  
 
Sattar et al (23), in a post-hoc analysis regarding new-onset diabetes and glycemia in OSLER trial 
population, showed a similar change in both HbA1c and fasting plasma glucose over 48 weeks, in both 
treatment arms.  
 
GLAGOV (2016) 
In the multicenter, double-blind, placebo-controlled Global Assessment of Plaque Regression with a 
PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV)  randomized controlled trial 
(24), 968 patients were enrolled to receive either evolocumab 420mg monthly (n=484) or respective 
placebo (n=484), via subcutaneous injections, for 76 weeks. Inclusion criteria were patients greater than 
18 years old and at least 1 epicardial coronary stenosis of at least 20% on coronary angiography and had 
a target vessel suitable for imaging with less than 50% visual obstruction. In addition, patients also 
required to have been treated with a stable statin dose for at least 4 weeks and to have an LDL-c level 
of 80 mg/dL or higher, or between 60 to 80 mg/dL with 1 major or 3 minor cardiovascular risk factors.  
The primary efficacy end-point was the nominal change in percent atheroma volume (PAV) and the 
secondary efficacy end-point was the nominal change in normalized total atheroma volume (TAV), both 
measured by intravascular ultrasonography (IVUS) and calculated as the value at 78 weeks minus the 
value at baseline, respectively, in evolocumab group (n=423) and placebo group (n=423). 
PAV did not change in placebo group (0.05%, P=0.78 compared with baseline) and decreased by 0.95% 
in the evolocumab group (P<0.001 compared with baseline; between-group difference, -1.0% [95% CI, 
-1.8% to -0.64%]; P<0.001).  
TAV did not change in placebo group (-0.9mm3, P=0.45 compared with baseline) and decreased by 
5.8mm3 in evolocumab group (P<0.001 compared with baseline; between-group differences, -4.9mm3 
[95 CI, -7.3 to -2.5]; P<0.001). 
The prespecified subgroup analysis of change in PAV from baseline to week-78 follow-up showed 
treatment differences favoring the use of evolocumab. 
 
FOURIER (2017)  
In the Further Cardiovascular Outcomes Research with PCSK9 Inhibition with Elevated Risk 
(FOURIER) study (11), a randomized, double-blind, placebo-controlled, multinational clinical trial, 
27564 patients between 40 and 85 years who had clinically evident CVD and fasting LDL-c level of at 
least 70 mg/dL or non-HDL-c level of at least 100 mg/dL while they were taking optimized regimen of 
lipid-lowering therapy with statins, with or without ezetimibe, were assigned to receive either 
evolocumab (140mg every 2 weeks or 420 mg monthly, subcutaneously) (n=13784) or matching 
placebo (n=13780).  The median duration follow-up was 2.2 years. 
The primary end-point was a composite of cardiovascular death, myocardial infarction, stroke, 
hospitalization for unstable angina or coronary revascularization, which occurred in 1344 patients 
(9.8%) in evolocumab group and in 1563 patients (11.3%) in placebo group (HR 0.85; 95% CI, 0.79 to 
0.92; P<0.001). 
The secondary end-point was the composite of cardiovascular death, stroke or myocardial infarction, 
which occurred in 816 patients (5.9%) in evolocumab group and 1013 patients (7.4%) in placebo group 
(HR 0.80; 95% CI, 0.73 to 0.88; P<0.001). 
Despite this significantly risk reduction of 15% in primary end-point and 20% in secondary end-point, 
an exploratory analysis of each outcome individually showed that evolocumab had no statistical 
significant effect on cardiovascular death (P=0.62), death from any cause (P=0.54), hospitalization for 
unstable angina (P=0.89) and cardiovascular death or hospitalization for worsening heart failure 
(P=0.82), compared to placebo. Yet, myocardial infarction was reduced 27% (P<0.001), stroke was 
reduced 21% (P=0.01) and coronary revascularization was reduced 22% (P<0.001) in the evolocumab 
group when compared to placebo. 
Regarding lipid data, the mean percentage reduction in LDL-c level with evolocumab was 59% (95% 
CI, 58 to 60; P<0.001). This reduction was sustained over time and neutralizing antibodies did not 
develop in any patient. 
After FOURIER trial had been published, several post-hoc exploratory analysis emerged and brought 
some relevant results regarding different subgroups in FOURIER trial population. 
Giugliano RP et al (25)  compared the outcomes of evolocumab in 2 subgroups: patients with baseline 
LDL-c level of less than 70 mg/dL versus levels greater than 70 mg/dL and patients receiving a maximal-
potency background statin versus submaximal statin therapy. The authors found that evolocumab 
reduced the risk for the primary end-point by 20% (HR, 0.80; 95% CI, 0.60-1.07) in patients with an 
LDL-c level of less than 70 mg/dL and by 14% (HR, 0.86; 95% CI, 0.73-0.89) in patients with a LDL-
c level of at least 70 mg/dL, with no evidence of treatment effect modification by baseline LDL-c 
(P=0.65 for interaction). 
Likewise, evolocumab reduced either primary and secondary end-point in both background statin 
therapy subgroups, with no evidence of treatment effect modification owing to intensity of background 
statin therapy (P=0.71 for interaction). 
Sabatine MS et al (26), examined the cardiovascular efficacy and safety of evolocumab by baseline 
diabetes status. A total of 11031 (40%) had diabetes and 16533 (60%) did not have diabetes at baseline. 
When analyzing the placebo group alone, patients with diabetes were at significantly greater risk for the 
primary end-point (HR 1.26, 95% CI 1.13-1.40, p<0.0001) and secondary end-point (HR 1.40, 95% CI 
1.23-1.60, p<0.0001), than those without diabetes. Moreover, evolocumab significantly reduced the 
primary and secondary end-point in patients with and without diabetes at baseline, compared to placebo.  
Nevertheless, the absolute risk reduction tended to be greater in patients with diabetes (ARR 2.7%, 95% 
CI 0.7-4-8) when compared to those without diabetes (ARR 1.6% (95% CI 0.1-3.2)).  
The authors also found that the risk of new-onset diabetes in patients without diabetes at baseline was 
not increased with the use of evolocumab, nor did it worsen the glycaemia. 
Bohula EA et al (27), explored the effect of evolocumab stratified by baseline high-sensitivity C reactive 
protein (hs-CRP) level. 
The analytic cohort was composed of 27495 patients of the trial population, categorized into 3 
subgroups: 7981 patients with a low-baseline hsCRP level (<1 mg/dL), 11177 with an intermediate 
hsCRP (1-3 mg/dL) and 8337 with a high hsCRP (>3 mg/dL). 
First, among the 13740 patients assigned to placebo arm in FOURIER trial, the higher the baseline 
hsCRP levels were, the greater the rates of cardiovascular events were. Second, the relative risk 
reduction with evolocumab versus placebo for both the primary and secondary end-points was consistent 
across baseline hsCRP strata. Yet, the ARR for primary and secondary end-points with evolocumab 
tended to be the highest in those with baseline hsCRP level >3 mg/dL, with a number needed to treat 
(NNT) for the primary end-point of 38 in those in this stratum versus 56 in those with the lowest baseline 
hsCRP levels.  Even among patients achieving very low LDL-c concentrations (<20 mg/dL) 1 month 
after randomization, the adjusted event rate was as greater as the higher the baseline hsCRP levels were. 
Bonaca MP et al (28) stratified the study population according to symptomatic peripheral artery disease 
(PAD). A total of 3642 (13.2%) had a history of symptomatic lower extremity PAD at baseline of whom 
a total of 2137 patients had concomitant prior myocardial infarction (MI) or prior stroke and 1505 
patients had no history of neither MI nor stroke.  
When analyzing placebo arm alone, patients with PAD had significantly higher rates of both the primary 
and secondary end-point in comparison with patients without PAD. Likewise, patients with PAD and 
concomitant MI or stroke had higher rates of CV events than those without. Nevertheless, patients with 
PAD and no prior MI or stroke, still had higher rates of CV death, MI or stroke than patients with prior 
MI or stroke and no symptomatic PAD (10.3% versus 7.6%; adjusted HR, 2.07; 95% CI, 1.42-3.01; 
P=0.0001).  Last, patients with symptomatic PAD had higher rates of major adverse limb events 
(MALE).  
In terms of MACE, in patients with PAD evolocumab reduced primary end-point by 21% (2.5-year 
Kaplan Meier rate, 13.3% versus 16.8%; HR, 0.79; 95% CI, 0.66-0.94; P=0.0098) and secondary end-
point by 27% (9.5% versus 13.0%; HR, 0.73; 95% CI, 0.59-0.91; P=0.0040) compared to placebo. This 
reduction was consistent even in patients with PAD without prior MI or stroke. 
Furthermore, LDL-c lowering with evolocumab reduced the risk of MALE by 42% in the overall 
population (0.27% versus 0.45%; HR, 0.58; 95% CI, 0.38-0.88; P=0.00093; ARR, 0.18%). 
Last, when looking at the composite of MACE or MALE in patients with PAD and no prior MI or stroke, 
evolocumab resulted in an ARR at 2.5 years of 6.3% yielding NNT of 16.  
Sabatine MS et al (29) analyzed the effects of evolocumab by severity and extent of coronary artery 
disease. The patients were stratified based on the number of prior MIs (more than 2 versus less than 2), 
the timing of prior MIs (less than 2 years versus more than 2 years) and the presence of residual 
multivessel coronary disease defined as ≥ 40% stenosis in  ≥ 2 large vessels. 
When analyzing the placebo arm alone, both the primary and secondary end-point were significantly 
higher in all strata. 
When considering the benefit of evolocumab versus placebo, regarding timing of prior MI, evolocumab 
reduced primary end-point by 20% (HR, 0.80, 0.71-0.91) in those with a more recent MI versus 5% 
(HR, 0.95) in those without. This result was consistent in the rest strata, where evolocumab reduced the 
primary end-point by 18% in those with multiple prior MIs (HR, 0.82, 0.72-0.93) and 21% (HR 0.79, 
0.69-0.91) in those with multivessel disease. 
Table 1 and 2 provide a compilation of the available data from the original articles regarding hazard 
ratios, absolute risk reductions and number need to treat with respect to primary and secondary end-
point of the FOURIER trial population. 
 
 
 
EBBINGHAUS (2017)  
The Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk 
Subjects (EBBINGHAUS) study (30), assessed the cognitive function from a subgroup of patients from 
the FOURIER trial, using the Cambridge Neuropsychological Test Automated Battery (CANTAB). 
Patients were enrolled previously to the first dose administration in FOURIER trial. The inclusion 
criteria were the ones described previously in FOURIER trial. Patients were excluded if any condition 
could confound the study results, such as dementia or any cognitive impairment. A total of 1974 patients 
were enrolled. 
The primary end point was the score on the spacial working memory strategy index of executive function 
(scores range from 4 to 28, with lower scores representing more efficient use of strategy and planning).  
The three secondary end points were working memory, episodic memory and psychomotor speed. 
The primary analysis population included 1204 patients, out of the total 1974, who had baseline 
CANTAB assessment before or on the day of the first dose of evolocumab (n=586) or placebo (n=618) 
and had at least one follow-up CANTAB assessment. This analysis was a noninferiority comparison of 
the mean change in the primary end point from baseline over time. The median duration of follow-up 
was 19.4 months in the primary analysis population.  
In terms of outcomes, the mean change from baseline over time in the primary end-point did not differ 
significantly between the two study groups; the raw score at baseline was 17.8 in both groups, and mean 
change from baseline in the score was -0.21+/- 2.62 in  evolocumab group and -0.29 +/- 2.81 in  placebo 
group (P<0.001 for noninferiority and P=0.85 for superiority). With respect to the three secondary end 
points, the mean change in raw scores from baseline also did not differ significantly between two study 
groups. 
The full analysis population included the 1204 from the primary analysis population plus the 770 
patients whose first CANTAB assessment occurred after the day on which the first dose of evolocumab 
(n=983) or placebo (n=990) was administered. No significantly differences were observed between two 
study groups. 
Between-group differences assessment showed no significantly differences favoring either the use of 
evolocumab or the use of placebo.  
At the final visit, a total of 1581 patients in the EBBINGHAUS study performed retrospective self-
assessments of their executive and memory function comparing current level of everyday functioning 
with their level at the beginning of the trial, using the Everyday Cognition tool (ECog). No significant 
between-group differences were observed in scores on individual domains (P=0.83 for memory domain; 
P=0.28 for executive functioning domain) or total score (P=0.42). 
These results support either objectively (via CANTAB assessment) and subjectively (via ECog) that the 
use of evolocumab does not cause any cognitive impairment compared to placebo. 
 
Studies involving Bococizumab 
SPIRE (2017)  
The Studies of PCSK9 Inhibition and the Reduction of Vascular Events (SPIRE) program for the 
development of bococizumab consists of two parts: the six SPIRE lipid-lowering studies and the SPIRE-
1 and SPIRE-2 event-driven cardiovascular outcome trials (8, 31). The former did not meet the inclusion 
criteria for this report and the last is described in this article. 
The SPIRE-1 and SPIRE-2 studies are two randomized, placebo-controlled, multinational clinical trials 
which aim to evaluate the clinical efficacy and the safety of bococizumab. During the conduct of these 
two trials, the sponsor discontinued further development of bococizumab on November 1, 2016, because 
data from the six SPIRE lipid-lowering trial became available indicating that the drug was associated 
with the development antidrug antibodies that significantly attenuated LDL-c lowering over time. In 
addition, even among patients who were antibody negative, bococizumab was associated with a wide 
variation in LDL-c reduction(31). Despite the discontinuation of bococizumab and the prematurely stop 
of SPIRE-1 and SPIRE-2 trials, the unblinded data collected between October 2013 until November 
2016 were analyzed and the results are described here (8). 
The inclusion criteria were to have either a previous cardiovascular event or history of diabetes, chronic 
kidney disease, or peripheral vascular disease with additional cardiovascular risk condition or a history 
of familial hypercholesteremia, to have one or more additional cardiovascular risk factors and age of at 
least 50 years for men and 60 years for women. Patients were also required to have an LDL-c level ≥70 
mg/dl or non-HDL level ≥ 100 mg/dl in SPIRE-1 and to have a LDL-c level ≥ 100 mg/dl or non-HDL 
≥ 130 mg/dl in SPIRE-2. Treatment with a statin during the previous 4 weeks was a condition met in all 
patients. 
At the time the sponsor stopped the trial a total of 16817 patients had been enrolled in SPIRE-1 trial to 
receive either bococizumab 150mg, twice a week, via subcutaneous injections (n=8408) or matching 
placebo (n=8392). A total of 10621 patients had enrolled in SPIRE-2 trial to received either 
bococizumab 150mg subcutaneously every two weeks (n=5312) or matching placebo (n=5309). By the 
time the trial was terminated, the median follow-up time was 7 months in SPIRE-1 and 12 months in 
SPIRE-2.  
The primary end-point of the two trials was a composite of cardiovascular death, non-fatal myocardial 
infarction, non-fatal stroke and hospitalization for unstable angina requiring urgent revascularization. 
In SPIRE-1 the primary end-point occurred in 173 patients each in bococizumab group and placebo 
group (HR 0.99; 95% CI, 0.80 to 1.22; P=0.94). In SPIRE-2 the primary end-point occurred in 179 
patients in bococizumab group and in 224 patients in placebo group (HR, 0.79; 95% CI, 0.65 to 0.97; 
P=0.02). In the combined analysis, the primary end-point occurred in 352 patients in bococizumab group 
and in 397 in placebo group (HR, 0.88; 95% CI, 0.76 to 1.02; P=0.08).  
In summary, bococizumab significantly reduced cardiovascular events in the higher risk patient group 
(SPIRE-2) but did it not in the lower risk patient group (SPIRE-1). 
 
Studies involving Alirocumab 
ODYSSEY OUTCOMES (2018) 
The ODYSSEY OUTCOMES trial (32) tested whether adding alirocumab to standard high intensity statin 
therapy, in post-acute coronary syndrome (ACS) patients would improve their morbidity and mortality. 
In this multi-center, double-blind, placebo-controlled trial, the authors randomized 18924 patients, who 
were more than 40 years of age, had a recent ACS within 1 to 12 months prior to randomization  and 
who had an LDL-c level more than 70 mg/dl, or non-HDL-c level more than 100 mg/dl or a 
apolipoprotein B more than 80 mg/dl, despite maximal intensity-statin therapy, to receive either 
alirocumab (n=9462) 75mg  subcutaneously every two weeks or matching placebo (n=9462).  
Protocol-specific dose-adjustments were performed to target an LDL-c level of 25 to 50 mg/dl and to 
avoid sustained levels below 15mg/dl. If patients achieved LDL-c levels above 50 mg/dL alirocumab 
was up-titrated from 75mg to 150mg. If patients achieved levels below 15 mg/dL in two consecutives 
measurements, patients were switched to placebo arm. LDL-c levels were considered acceptable 
between 15-25 mg/dl with alirocumab 75mg, but down-titrated if alirocumab 150mg. 
Median duration of follow-up was 2.8 years. 
The primary efficacy end-point was a composite of death from coronary heart disease (CHD), nonfatal 
myocardial infarction, fatal or non-fatal ischemic stroke, or unstable angina requiring hospitalization. A 
total of 903 patients (9.5%) in the alirocumab group and 1052 patients (11.1%) in the placebo group 
(HR 0.85, 95% CI, 0.78-0.93, P<0.001) experienced the primary end-point. A prespecified subgroup 
analysis demonstrated the greatest benefit in those with an LDL-c level higher than 100 mg/dL at 
baseline (HR 0.76, 95% CI, 0.65-0.87) compared to those with LDL-c levels lower than 100 mg/dl. 
The major secondary efficacy end-point included: any CHD event; major CHD event; any CV event; 
composite of death from any cause, non-fatal MI or non-fatal ischemic stroke; death from CHD; death 
from CV causes; death from any cause. The hierarchical analysis showed significant results in the first 
four secondary end-points, but it was stopped after the first nonsignificant P value observed in death 
from CHD end-point (P=0.38), in accordance with the hierarchical testing plan.  
A total of 334 patients (3.5%) in the alirocumab group and 392 patients (4.1%) in the placebo group 
died (HR, 0.85; 95% CI, 0.73 to 0.98). 
Finally, the treatment was safe and well tolerated. The most frequent adverse event, which was rare, was 
local site-injection reactions (3.8% in alirocumab group versus 2.1% in placebo group, P<0.001). 
 
Table 3 provides a compilation of the studies previously described and summaries of their major 
findings. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Limitations 
Several limitations regarding original studies described here should be considered. 
GLAGOV trial examined the effects of disease progression only on patients presenting for a clinically 
indicated coronary angiography and focused only on atheroma volume and did not characterized the 
effects on atheroma morphology (24). 
The major limitation of FOURIER trial is the relatively short follow-up period compared to other lipid-
lowering trials (11). 
Post-hoc analysis of FOURIER trials are not truly randomized controlled trial, once the results are 
interpreted in a post-randomization subgroup stratification. Even with adequate multivariable 
adjustment, residual confounding may remain. 
In SPIRE program, the major limitation was the prematurely stop of the trial and discontinuation of the 
drug. Besides, the differences in baseline LDL-c levels and follow-up duration between SPIRE-1 and -
2 populations also constitute a limitation. 
In ODYSSEY OUTCOME trial, whether the safety and efficacy of alirocumab were influenced by the 
blinded dose-adjustment strategy, which was designed to mitigate the occurrence of very low levels of 
LDL-c constitutes a major limitation. Like in FOURIER trial, this trial cannot predict longer-term safety 
of treatment with a PCSK9 inhibitor (32). 
A limitation in all these trials is the infrequent use of ezetimibe, for which cardiovascular efficacy is 
established. 
 
 
 
 
Conclusions  
CVD are a major problem in our society and many efforts are being made to attenuate this issue (1,2,3). 
Reduction of LDL-c has been proven to reduce overall mortality, but some patients still cannot achieve 
current LDL-c goals (2). PCSK9 inhibitors might be an important therapeutic weapon in this setting.  
Evolocumab, alirocumab and bococizumab all proved to produce an incremental reduction on LDL-c 
plasma levels in patients already taking statins and ezetimibe (10). However, the last drug was not able to 
maintain its effects overtime because of development of antidrug antibodies which led to its 
discontinuation (31). Still, an analysis made with available data from the SPIRE-1 and 2 trials before its 
ending, showed no benefits of bococizumab in MACE reduction compared to placebo in SPIRE-1 and 
combined SPIRE-1 and 2 analysis, but a significant reduction was observed in SPIRE-2 population (8,31). 
The GLAGOV trial demonstrated for the very first time a regression of atherosclerotic plaque in patients 
using evolocumab compared to placebo when added to a statin background (24). Yet, whether if 
incremental LDL-c level reduction and plaque regression using evolocumab would prevent MACE was 
still uncertain. 
Following this, FOURIER trial showed a significant reduction in the composite end-point of major CV 
death, MI, stroke, hospitalization for unstable angina or coronary revascularization, but not on all-cause 
mortality (11). Importantly, these benefits came with no offsetting neurocognitive impairment, as 
demonstrated in EBBINGHAUS trial, or other adverse events (22,30).  
Subgroup analysis of FOURIER trial demonstrated that patients with baseline diabetes, hs-CRP baseline 
level >3 mg/dL, baseline PAD, more than two MI, prior MI less than two years and multivessel residual 
coronary disease would benefit the most from evolocumab use (26-29). Give the currently high cost of the 
drug (33), such finding shall be taken into consideration regarding which patients would benefit the most 
from drug’s clinical potential. 
Alirocumab showed a significant reduction in MACE comparing to placebo, similarly to FOURIER 
trial. This benefit was more pronounced among patients who had an LDL-c baseline level of at least 100 
mg/dL, like in SPIRE-2 trial population. This drug also had an impact on overall mortality (32). 
To conclude, evolocumab and alirocumab, consistently lowered LDL-c and reduced MACE (11,32) with 
no appreciable adverse events (22,30). Alirocumab showed a reduction in overall mortality (32). 
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Figure caption  
 
 
Figure 1. PCSK9 Inhibitors mechanism of action: A) PCSK9 binds to LDL-receptors and 
targets them for degradation; B) PCSK9 Inhibitors allow LDL-receptor recycling to hepatic cell 
surface. 
 
 
Figure 2. Flowchart showing literature search method n, number of articles. 
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Table 1. Primary and secondary end-point Hazard Ratios by FOURIER trial subgroup population 
 
Outcome 
 
Hazard Ratio (95% CI) 
 
 Total 
population 
Subgroup population 
  PAD 
 
hs-CRP 
 
High-risk features Diabetes LDL-c Statin Therapy 
  w wo <1 
mg/dL 
1 to 3 
mg/dL 
>3 
mg/dl 
MI < 2y MI > 2y >2 MI < 2 
MI 
 
w/ 
RMD 
wo/ RMD w wo <70 
mg/dL 
>70 
mg/dL 
Maxi
mal 
dose 
Submaximal 
dose 
 
 
Primary 
End-point 
 
 
 
0.85 (0.79-0.92) 0.79 
(0.66-
0.94) 
0.86 
(0.80-
0.93) 
0.82 
(0.70-
0.95) 
0.93 
(0.83-
1.05) 
0.80 
(0.71-
0.90) 
0.80 
(0.71-
0.91) 
0.95 
(0.85-
1.05) 
0.82 
(0.72-
0.93) 
0.92 
(0.84-
1.02) 
0.79 
(0.69-
0.91) 
0.93 
(0.85-
1.02) 
0.83 
(0.75-
0.93) 
0.87 
(0.79-
0.96) 
0.80 
(0.60-
1.07) 
0.86 
(0.79-
0.92) 
0.86 
(0.79-
0.92) 
0.85 (0.78-
0.93) 
Secondary 
end-point 
0.80 (0.73-0.88) 0.73 
(0.59-
0.91) 
0.81 
(0.73-
0.90) 
0.81 
(0.66-
0.99) 
0.87 
(0.75-
1.02) 
0.73 
(0.63-
0.85) 
0.79 
(0.67-
0.94) 
0.92 
(0.84-
1.02) 
0.79 
(0.67-
0.94) 
0.84 
(0.74-
0.96) 
0.70 
(0.58-
0.84) 
0.89 
(0.70-
1.00) 
0.82 
(0.72-
0.93) 
0.78 
(0.72-
0.93) 
0.70 
(0.48-
1.01) 
0.81 
(0.73-
0.89) 
0.78 
(0.66-
0.92) 
0.81 (0.72-
0.90) 
 
Abbreviations: MI, myocardial infarction; PAD, peripheral artery disease; RMD, residual multivessel disease (defined as stenosis >40% in >2 large vessels);  hs-CRP, high-sensitivity C-Reactive Protein; w, with; wo, without; y, years 
 
  
 
 
 
Table 2. Primary and secondary end-point Absolute Risk Reduction (ARR) and respective Number Needed to Treat (NNT) by FOURIER trial subgroup population 
 
Outcome 
 
ARR (NNT) 
 Total 
population 
Subgroup population 
  PAD 
 
hs-CRP 
 
High-risk features Diabetes LDL-c Statin Therapy 
  w wo <1 
mg/dL 
1 to 3 
mg/dL 
>3 
mg/dl 
MI < 2y MI > 2y >2 MI < 2 
MI 
 
w/ 
RMD 
wo/ 
RMD 
w wo <70 
mg/dL 
>70 
mg/dL 
Maxima
l dose 
Submax
imal 
dose 
 
 
Primary 
End-point 
 
 
 
1.5% (67) 3.5% 
(29) 
1.6% 
(63) 
1.6% 
(63) 
1.8% 
(56) 
2.6% 
(38) 
3.4% 
(29) 
0.8% 
(125) 
3.7% 
(27) 
1.3% 
(77) 
3.6% 
(28) 
1.2% 
(83) 
2.7% 
(37) 
1.6% 
(63) 
2.3% 
(43) 
1.5% 
(67) 
1.8% 
(56) 
1.5% 
(67) 
Secondary 
end-point 
1.5% (67) 3.5% 
(29) 
1.4% 
(71) 
0.8% 
(125) 
2.0% 
(50) 
3.0% 
(33) 
2.9% 
(34) 
1.0% 
(100) 
2.6% 
(38)) 
1.7% 
(59) 
3.4% 
(29) 
1.3% 
(77) 
2.0% 
(50) 
2.0% 
(50) 
2.1% 
(48) 
1.4% 
(71) 
1.8% 
(56) 
1.8% 
(56) 
 
 
Abbreviations:ARR, absolute risk reduction;  MI, myocardial infarction; NNT, number needed to treat; PAD, peripheral artery disease; RMD, residual multivessel disease (defined as stenosis >40% in >2 large vessels);  hsCRP, high-sensitivity C-
Reactive Protein; w, with; wo, without; y, years 
 
 Table 3. Some of the major studies on clinical outcomes of PCSK9 Inhibitors and summaries of their conclusion 
 
 
Study n Intervention End-point Major Findings 
OSLER (2015) 4465 EVO SC plus SOC 
(420 mg Q1M) vs. 
SOC alone in 
OSLER-1 
EVO SC (140mg 
Q2W or 420mg 
Q1M) plus SOC vs. 
SOC alone in 
OSLER-2 
Incidence of 
adverse events 
Adverse events were reported more frequently in the EVO 
group 
EVO group had a significantly lower rates of all 
cardiovascular events than did the patients in the SOC group 
No differences between groups regarding glycaemia and new 
onset-diabetes 
GLAGOV (2016) 968 EVO SC (420mg 
Q1M) vs. PLA 
Nominal change in 
PAV and nominal 
change in TAV 
EVO significantly reduces PAV and TAV compared with 
PLA 
FOURIER (2017) 27564 EVO SC (140mg 
Q2W or 420 Q1M) 
vs. PLA 
Primary end-point: 
CV death, MI, 
stroke, 
hospitalization for 
UA or CR 
 
Secondary end-
point: CV death, 
MI, stroke 
EVO significantly reduced both the primary and secondary 
end-point compared to PLA 
 
EVO did not reduce all-cause mortality compared to PLA 
 
EVO was equally effective in reducing MACE in patients 
with LDL-c <70mg/dL vs >70mg/dL and maximal statin dose 
vs submaximal statin-dose 
 
EVO significantly reduced MACE in patients with and 
without diabetes 
 
EVO reduced MACE across hsCRP strata with greater ARR 
in patients with higher-baseline hsCRP levels 
 
EVO significantly reduced MACE and MALE with greater 
ARR in patients with PAD versus without 
 
EVO significantly reduced MACE in patients closer to their 
most recent MI, with multiple prior MI or with multivessel 
CAD with greater ARR in this subgroup of patients 
EBBINGHAUS (2017) 1974 EVO SC (140mg 
Q2W or 420 Q1M) 
vs. PLA 
Score on the 
spacial working 
memory strategy 
index of executive 
function 
No differences between groups regarding cognitive function 
SPIRE (2016) 27438 total 
 
16817 in 
SPIRE-1 
 
10621 in 
SPIRE-2 
 
BOCO SC (150mg 
Q2W) vs. PLA 
Composite of CV 
death, non-fatal 
MI, non-fatal 
stroke or 
hospitalization for 
UA requiring 
urgent 
revascularization 
BOCO did not significantly reduced MACE in SPIRE-1 
 
BOCO significantly reduced MACE in SPIRE-2 
 
BOCO did not significantly reduced MACE in the combined 
groups 
ODYSSEY 
OUTCOMES (2018) 
18924 ALI SC (75 or 150 
mg Q2W) vs PLA 
Composite of CHD 
disease, nonfatal 
MI, fatal or non-
fatal IS, or UA 
requiring 
hospitalization 
ALI significantly reduced MACE 
 
ALI reduced overall mortality 
 
Abbreviations:ALI, alirocumab; ARR, absolute risk reduction; BOCO, bococizumab; CAD, coronary artery disease; CHD, coronary heart disease death; CR, cardiac 
revascularization; CV, cardiovascular; EVO, evolocumab; IS, ischemic stroke;  MACE, major adverse cardiovascular events; MALE, major adverse limb events; MI, 
myocardial infarction; PAD, peripheral artery disease; PAV, percent atheroma volume; PLA, placebo; Q1M, every one month; Q2W, every two weeks; SC, 
subcutaneous; SOC, standard of care; TAV, normalized total atheroma volume; UA, unstable angina; hsCRP, high-sensitivity C-reactive protein 
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ANEXO 
 
Normas de Publicação da Revista Portuguesa de Cardiologia 
A Revista Portuguesa de Cardiologia, órgão oficial da Sociedade 
Portuguesa de Cardiologia, é uma publicação científica internacional 
destinada ao estudo das doenças cardiovasculares.
Publica artigos em português na sua edição em papel e em portu-
guês e inglês na sua edição online, sobre todas as áreas da Medicina 
Cardiovascular. Se os artigos são publicados apenas em inglês, esta 
versão surgirá simultaneamente em papel e online. Inclui regularmen-
te artigos originais sobre investigação clínica ou básica, revisões te-
máticas, casos clínicos, imagens em cardiologia, comentários editoriais 
e cartas ao editor. Para consultar as edições online deverá aceder 
através do link www.revportcardiol.org.
Todos os artigos são avaliados antes de serem aceites para publi-
cação por peritos designados pelos Editores (peer review). A sub-
missão de um artigo à Revista Portuguesa de Cardiologia implica que 
este nunca tenha sido publicado e que não esteja a ser avaliado para 
publicação noutra revista. 
Os trabalhos submetidos para publicação são propriedade da Re-
vista Portuguesa de Cardiologia e a sua reprodução total ou parcial 
deverá ser convenientemente autorizada. Todos os autores deverão 
enviar a Declaração de Originalidade, conferindo esses direitos à 
RPC, na altura em que os artigos são aceites para publicação.
Envio de manuscritos
Os manuscritos para a Revista Portuguesa de Cardiologia são en-
viados através do link http://www.ees.elsevier.com/repc. Para enviar 
um manuscrito, é apenas necessário aceder ao referido link e seguir 
todas as instruções que surgem. 
Responsabilidades Éticas
Os autores dos artigos aceitam a responsabilidade definida pelo 
Comité Internacional dos Editores das Revistas Médicas (consultar 
www.icmje.org).
Os trabalhos submetidos para publicação na Revista Portuguesa de 
Cardiologia devem respeitar as recomendações internacionais sobre 
investigação clínica (Declaração de Helsínquia da Associação Médica 
Mundial, revista recentemente) e com animais de laboratório (So-
ciedade Americana de Fisiologia). Os estudos aleatorizados deverão 
seguir as normas CONSORT.
Informação sobre autorizações
A publicação de fotografias ou de dados dos doentes não devem 
identificar os mesmos. Em todos os casos, os autores devem apre-
sentar o consentimento escrito por parte do doente que autorize a 
sua publicação, reprodução e divulgação em papel e na Revista Portu-
guesa de Cardiologia. Do mesmo modo os autores são responsáveis 
por obter as respectivas autorizações para reproduzir na Revista 
Portuguesa de Cardiologia todo o material (texto, tabelas ou figuras) 
previamente publicado. Estas autorizações devem ser solicitadas ao 
autor e à editora que publicou o referido material.
Conflito de interesses
Cada um dos autores deverá indicar no seu artigo se existe ou não 
qualquer tipo de Conflito de Interesses.
Declaração de originalidade
O autor deverá enviar uma declaração de originalidade. Ver anexo I
Protecção de dados
Os dados de carácter pessoal que se solicitam vão ser tratados num 
ficheiro automatizado da Sociedade Portuguesa de Cardiologia (SPC) 
com a finalidade de gerir a publicação do seu artigo na Revista Por-
tuguesa de Cardiologia (RPC). Salvo indique o contrário ao enviar o 
artigo, fica expressamente autorizado que os dados referentes ao seu 
nome, apelidos, local de trabalho e correio electrónico sejam publica-
dos na RPC, bem como no portal da SPC (www.spc.pt) e no portal 
online www.revportcardiol.org, com o intuito de dar a conhecer a 
autoria do artigo e de possibilitar que os leitores possam comunicar 
com os autores.
INSTRUÇÕES AOS AUTORES
Todos os manuscritos deverão ser apresentados de acordo com as 
normas de publicação. Pressupõe-se que o primeiro autor é o repon-
sável pelo cumprimento das normas e que os restantes autores conhe-
cem, participam e estão de acordo com o conteúdo do manucrito.
1. Artigos Originais
Apresentação do documento:
• Com espaço duplo, margens de 2,5 cm e páginas numeradas.
• Não deverão exceder 5.000 palavras, contadas desde a primeira à 
última página, excluindo as tabelas.
• Consta de dois documentos: primeira página e manuscrito
• O manuscrito deve seguir sempre a mesma ordem: a) resumo estru-
turado em português e palavras-chave; b) resumo estruturado em inglês 
e palavras-chave; c) quadro de abreviaturas em português e em inglês; 
d) texto; e) bibliografia; f) legendas das figuras; g) tabelas (opcional) e h) 
figuras (opcional)-
Primeira página
Título completo (menos de 150 caracteres) em português e em inglês.
Nome e apelido dos autores pela ordem seguinte: nome próprio, 
seguido do apelido (pode conter dois nomes)
Proveniência (Serviço, Instituição, cidade, país) e financiamento caso 
haja.
Endereço completo do autor a quem deve ser dirigida a corres-
pondência, fax e endereço electrónico.
Faz-se referência ao número total de palavras do manuscrito (ex-
cluindo as tabelas).
Resumo estruturado
O resumo, com um máximo de 250 palavras, está dividido em quatro 
partes: a) Introdução e objectivos; b) Métodos; c) Resultados e d) 
Conclusões.
Deverá ser elucidativo e não inclui referências bibliográficas nem 
abreviaturas (excepto as referentes a unidades de medida).
Inclui no final três a dez palavras-chave em português e em inglês. 
Deverão ser preferencialmente seleccionadas a partir da lista publica-
da na Revista Portuguesa de Cardiologia, oriundas do Medical Subject 
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Portuguesa de Cardiologia
Headings (MeSH) da National Libray of Medicine, disponível em: 
www.nlm.nihgov/mesh/meshhome.html.
O resumo e as palavras-chave em inglês devem ser apresentados 
da mesma forma.
Texto
Deverá conter as seguintes partes devidamente assinaladas: a) In-
trodução; b) Métodos; c) Resultados; d) Discussão e e) Conclusões. 
Poderá utilizar subdivisões adequadamente para organizar cada uma 
das secções.
As abreviaturas das unidades de medida são as recomendadas pela 
RPC (ver Anexo II).
Os agradecimentos situam-se no final do texto.
Bibliografia
As referências bibliográficas deverão ser citadas por ordem numérica 
no formato ‘superscript’, de acordo com a ordem de entrada no texto.
As referências bibliográficas não incluem comunicações pessoais, 
manuscritos ou qualquer dado não publicado. Todavia podem estar 
incluídos, entre parêntesis, ao longo do texto.
São citados abstracts com menos de dois anos de publicação, 
identificando-os com [abstract] colocado depois do título.
As revistas médicas são referenciadas com as abreviaturas utiliza-
das pelo Index Medicus: List of Journals Indexed, tal como se publi-
cam no número de Janeiro de cada ano. Disponível em:   http://www.
ncbi.nlm.nih.gov/entrez/citmatch_help.html#JournalLists.
O estilo e a pontuação das referências deverão seguir o modelo 
Vancouver 3.
Revista médica: Lista de todos os autores. Se o número de autores 
for superior a três, incluem-se os três primeiros, seguidos da abreviatu-
ra latina et al. Exemplo:
 17. Sousa PJ, Gonçalves PA, Marques H et al. Radiação na AngioTC 
cardíaca; preditores de maior dose utilizada e sua redução ao lon-
go do tempo. Rev Port cardiol, 2010; 29:1655-65
Capítulo em livro: Autores, título do capítulo, editores, título do 
livro, cidade, editora e páginas. Exemplo:
 23. Nabel EG, Nabel GJ. Gene therapy for cardiovascular disease. 
En: Haber E, editor. Molecular cardiovascular medicine. New York: 
Scientific American 1995. P79-96.
Livro: Cite as páginas específicas. Exemplo:
 30. Cohn PF. Silent myocardial ischemia and infarction. 3rd ed. New 
York: Mansel Dekker; 1993. P. 33.
Material electrónico: Artigo de revista em formato electrónico. 
Exemplo:
 Abood S. Quality improvement initiative in nursing homes: the 
ANA acts it an advisory role. Am J Nurs. [serie na internet.] 2002 
Jun citado 12 Ago 2002:102(6): [aprox. 3] p. Disponível em: http://
www.nursingworld.org/AJN/2002/june/Wawatch.htm
. A Bibliografia será enviada como texto regular, nunca como nota de 
rodapé. Não se aceitam códigos específicos dos programas de gestão 
bibliográfica.
1. Figuras
As figuras correspondentes a gráficos e desenhos são enviadas no for-
mato TIFF ou JPEG de preferência, com uma resolução nunca inferior 
a 300 dpi e utilizando o negro para linhas e texto. São alvo de numera-
ção árabe de acordo com a ordem de entrada no texto.
• A grafia, símbolos, letras, etc, deverão ser enviados num tamanho que, 
ao ser reduzido, os mantenha claramente legíveis. Os detalhes especiais 
deverão ser assinalados com setas contrastantes com a figura.
• As legendas das figuras devem ser incluídas numa folha aparte. No 
final devem ser identificadas as abreviaturas empregues por ordem 
alfabética.
• As figuras não podem incluir dados que dêem a conhecer a 
proveniência do trabalho ou a identidade do paciente. As fotogra-
fias das pessoas devem ser feitas de maneira que estas não sejam 
identificadas ou incluir-se-á o consentimento por parte da pessoa 
fotografada.
Tabelas
São identificadas com numeração árabe de acordo com a ordem de 
entrada no texto.
Cada tabela será escrita a espaço duplo numa folha aparte.
• Incluem um título na parte superior e na parte inferior são refe-
ridas as abreviaturas por ordem alfabética.
• O seu conteúdo é auto-explicativo e os dados que incluem não 
figuram no texto nem nas figuras.
2. Cartas ao Editor
Devem ser enviadas sob esta rubrica e referem-se a artigos publica-
dos na Revista. Serão somente consideradas as cartas recebidas no 
prazo de oito semanas após a publicação do artigo em questão.
• Com espaço duplo, com margens de 2,5 cm.
• O título (em português e em inglês), os autores (máximo quatro), 
proveniência, endereço e figuras devem ser especificados de acordo 
com as normas anteriormente referidas para os artigos originais.
• Não podem exceder as 800 palavras.
• Podem incluir um número máximo de duas figuras. As tabelas 
estão excluídas.
3. Casos Clínicos
Devem ser enviados sob esta rubrica.
• A espaço duplo com margens de 2,5 cm.
• O título (em português e em inglês) não deve exceder 10 palavras
Os autores (máximo oito) proveniência, endereço e figuras serão 
especificados de acordo com as normas anteriormente referidas para 
os artigos originais.
O texto explicativo não pode exceder 3.000 palavras e contem in-
formação de maior relevância. Todos os símbolos que possam constar 
nas imagens serão adequadamente explicados no texto.
Contêm um número máximo de 4 figuras e pode ser enviado mate-
rial suplementar, como por exemplo vídeoclips.
4. Imagens em Cardiologia
• A espaço duplo com margens de 2,5 cm.
• O título (em português e em inglês) não deve exceder oito palavras
• Os autores (máximo seis), proveniência, endereço e figuras serão 
especificados de acordo com as normas anteriormente referidas pa-
ra os artigos originais.
• O texto explicativo não pode exceder as 250 palavras e contem 
informação de maior relevância, sem referências bibliográficas. To-
dos os símbolos que possam constar nas imagens serão adequada-
mente explicados no texto.
• Contêm um número máximo de quatro figuras.
5. Material adicional na WEB
A Revista Portuguesa de Cardiologia aceita o envio de material 
electrónico adicional para apoiar e melhorar a apresentação da 
sua investigação científica. Contudo, unicamente se considerará 
para publicação o material electrónico adicional directamente 
relacionado com o conteúdo do artigo e a sua aceitação final 
dependerá do critério do Editor. O material adicional aceite não 
será traduzido e publicar-se-á electronicamente no formato da 
sua recepção.
Para assegurar que o material tenha o formato apropriado reco-
mendamos o seguinte:
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Símbolos, abreviaturas de medidas ou estatística
 Formato Extensão Detalhes
Texto Word .doc ou docx Tamanho máximo 300 Kb
Imagem JPG .jpg Tamanho máximo 10MB
Audio MP3 .mp3 Tamanho máximo 10MB
Vídeo WMV .wmv Tamanho máximo 30MB
Os autores deverão submeter o material no formato electró-
nico através do EES como arquivo multimédia juntamente com 
o artigo e conceber um título conciso e descritivo para cada 
arquivo.
Do mesmo modo, este tipo de material deverá cumprir também 
todos os requisitos e responsabilidades éticas gerais descritas nes-
sas normas.
O Corpo Redactorial reserva-se o direito de recusar o material 
electrónico que não julgue apropriado.
ANEXO I
DECLARAÇÃO
Declaro que autorizo a publicação do manuscrito:
Ref.ª ........................................................................................
Título  ...........................................................................................
........................................................................................................
.........................................................................................................
........................................................................................................
do qual sou autor ou c/autor.
Declaro ainda que presente manuscrito é original, não foi 
objecto de qualquer outro tipo de publicação e cedo a inteira 
propriedade à Revista Portuguesa de Cardiologia, ficando a 
sua reprodução, no todo ou em parte, dependente de prévia 
autorização dos editores.
Nome dos autores: 
 .............................................................................................
.................................................................................................. 
.........................................................................................................
Assinaturas: 
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Designação
Ampere
Ano
Centímetro quadrado
Contagens por minuto
Contagens por segundo
Curie
Electrocardiograma
Equivalente
Grau Celsius
Grama
Hemoglobina
Hertz
Hora
Joule
Litro
Metro
Minuto
Molar
Mole
Normal (concentração)
Ohm
Osmol
Peso
Pressão parcial de CO2
Pressão parcial de O2
Quilograma
Segundo
Semana
Sistema nervoso central
Unidade Internacional
Volt
Milivolt
Volume
Watts
Estatística:
Coeficiente de correlação
Desvio padrão (standard)
Erro padrão (standard) da média
Graus de liberdade
Média
Não significativa
Número de observações
Probabilidade
Teste «t» de Student
Português
A
ano
cm2
cpm
cps
Ci
ECG
Eq
°C
g
Hb
Hz
h
J
L ou L
m
min
M
mol
N
Ω
osmol
peso
pCO2
pO2
kg
s
Sem
SNC
UI
V
mV
Vol
W
r
DP
EPM
gl
χ
NS
n
p
teste t
Inglês
A
yr
cm2
cpm
cps
Ci
ECG
Eq
°C
g
Hb
Hz
h
J
I ou L
m
min
M
mol
N
Ω
osmol
WT
pCO2
pO2
kg
sec
Wk
CNS
IU
V
mV
Vol
W
r
SD
SEM
df
χ
NS
n
p
t test
